CN112399873B - 三唑乙醇酸氧化酶抑制剂 - Google Patents

三唑乙醇酸氧化酶抑制剂 Download PDF

Info

Publication number
CN112399873B
CN112399873B CN201980045610.4A CN201980045610A CN112399873B CN 112399873 B CN112399873 B CN 112399873B CN 201980045610 A CN201980045610 A CN 201980045610A CN 112399873 B CN112399873 B CN 112399873B
Authority
CN
China
Prior art keywords
triazole
carboxylic acid
nmr
compound
mhz
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980045610.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN112399873A (zh
Inventor
H·美格
M·X·费尔南德斯
R·赞博尼
E·阿克巴里罗马尼
M-A·比尤利
Y·勒布朗
P·塔库尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aofan Biotechnology Co
Cantero Treatment Co ltd
Original Assignee
Aofan Biotechnology Co
Cantero Treatment Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aofan Biotechnology Co, Cantero Treatment Co ltd filed Critical Aofan Biotechnology Co
Publication of CN112399873A publication Critical patent/CN112399873A/zh
Application granted granted Critical
Publication of CN112399873B publication Critical patent/CN112399873B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201980045610.4A 2018-07-06 2019-07-05 三唑乙醇酸氧化酶抑制剂 Active CN112399873B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862694918P 2018-07-06 2018-07-06
US62/694,918 2018-07-06
US201962827573P 2019-04-01 2019-04-01
US62/827,573 2019-04-01
PCT/US2019/040690 WO2020010309A1 (en) 2018-07-06 2019-07-05 Triazole glycolate oxidase inhibitors

Publications (2)

Publication Number Publication Date
CN112399873A CN112399873A (zh) 2021-02-23
CN112399873B true CN112399873B (zh) 2024-10-25

Family

ID=67441692

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980045610.4A Active CN112399873B (zh) 2018-07-06 2019-07-05 三唑乙醇酸氧化酶抑制剂

Country Status (14)

Country Link
US (2) US11401246B2 (https=)
EP (1) EP3817816A1 (https=)
JP (1) JP7348705B2 (https=)
KR (1) KR102865323B1 (https=)
CN (1) CN112399873B (https=)
AU (1) AU2019297523B2 (https=)
BR (1) BR112021000050A2 (https=)
CO (1) CO2021001277A2 (https=)
IL (1) IL279952B2 (https=)
MX (1) MX2021000051A (https=)
PE (1) PE20210859A1 (https=)
SA (1) SA521420951B1 (https=)
SG (1) SG11202012930RA (https=)
WO (1) WO2020010309A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021000050A2 (pt) 2018-07-06 2021-04-06 Orfan Biotech Inc. Inibidores de triazol glicolato oxidase
AU2020376792B2 (en) 2019-11-01 2025-10-02 Lilac Therapeutics, Inc. Heterocyclic carboxylate compounds as glycolate oxidase inhibitors
EP4087836B1 (en) * 2020-01-08 2025-10-08 Cantero Therapeutics, Inc. Processes for preparing triazole glycolate oxidase inhibitors
WO2022066933A1 (en) * 2020-09-24 2022-03-31 Chinook Therapeutics Canada, Inc. Pentafluoro-sulfanyl -substituted triazolyl compounds and methods of use thereof
JP2024538054A (ja) * 2021-10-11 2024-10-18 カンテロ セラピューティクス，インコーポレイティド 高シュウ酸尿症及び腎結石の治療のための１ｈ－１，２，３－トリアゾール－４－カルボン酸
WO2024109917A1 (zh) * 2022-11-25 2024-05-30 西藏海思科制药有限公司 一种三唑衍生物及其在医药上的应用
WO2024212137A1 (en) * 2023-04-12 2024-10-17 Cantero Therapeutics, Inc. Crystalline forms of a 1h-1, 2, 3-triazole-4-carboxylic acid compound

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63215680A (ja) * 1987-03-02 1988-09-08 Dai Ichi Seiyaku Co Ltd ベンゾピラノトリアゾ−ル誘導体
CN101307307A (zh) * 2008-07-11 2008-11-19 华东理工大学 一种乙醇酸氧化酶制剂、制备方法及应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187326B1 (en) 1998-12-29 2001-02-13 Thomas T. Yamashita Soil amendment composition
US7022702B2 (en) 2000-04-07 2006-04-04 Qlt Inc. Antiproliferative 1,2,3-thiadiazole compounds
CA2546353A1 (en) 2003-11-19 2005-06-09 Array Biopharma Inc. Bicyclic inhibitors of mek and methods of use thereof
US7829712B2 (en) 2004-09-20 2010-11-09 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
WO2013104573A1 (en) 2012-01-10 2013-07-18 F. Hoffmann-La Roche Ag Pyridazine amide compounds and their use as syk inhibitors
JP5455279B1 (ja) 2012-10-25 2014-03-26 アサヒグループホールディングス株式会社 ラテックスの増産方法
WO2014113485A1 (en) 2013-01-15 2014-07-24 Intermune, Inc. Lysophosphatidic acid receptor antagonists
US9392796B2 (en) 2013-03-15 2016-07-19 Spogen Biotech Inc. Plant growth-promoting bacteria and methods of use
FR3021843B1 (fr) 2014-06-06 2016-07-08 Lesaffre & Cie Methode et composition pour ameliorer la productivite de plantes non legumineuses
JP5866035B1 (ja) 2015-01-08 2016-02-17 アサヒグループホールディングス株式会社 有効分げつ促進方法
JP7148241B2 (ja) 2015-03-19 2022-10-05 三菱商事ライフサイエンス株式会社 植物の生長促進や根伸長促進効果且つ付加価値向上効果を有する酵母抽出物
EP3386949A4 (en) * 2015-12-07 2019-11-20 Wake Forest University Health Sciences GLYCOLATE OXIDASE INHIBITORS AND METHOD FOR USE FOR THE TREATMENT OF NIERSTEIN
MX2020006414A (es) 2017-12-29 2020-09-17 Biomarin Pharm Inc Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.
EP3731840A4 (en) 2017-12-29 2021-09-15 Orfan Biotech Inc. NADPH OXIDASE INHIBITORS AND THEIR USE
US11389456B2 (en) 2018-02-23 2022-07-19 Oxalurx, Inc. Compounds and methods for treating oxalate-related diseases
BR112021000050A2 (pt) 2018-07-06 2021-04-06 Orfan Biotech Inc. Inibidores de triazol glicolato oxidase
CA3143334A1 (en) 2019-06-19 2020-12-24 Biomarin Pharmaceutical Inc. Glycolate oxidase inhibitors for the treatment of disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63215680A (ja) * 1987-03-02 1988-09-08 Dai Ichi Seiyaku Co Ltd ベンゾピラノトリアゾ−ル誘導体
CN101307307A (zh) * 2008-07-11 2008-11-19 华东理工大学 一种乙醇酸氧化酶制剂、制备方法及应用

Also Published As

Publication number Publication date
IL279952A (en) 2021-03-01
AU2019297523B2 (en) 2025-04-17
EP3817816A1 (en) 2021-05-12
BR112021000050A2 (pt) 2021-04-06
SG11202012930RA (en) 2021-01-28
PE20210859A1 (es) 2021-05-18
KR20210041564A (ko) 2021-04-15
JP7348705B2 (ja) 2023-09-21
WO2020010309A9 (en) 2020-01-30
US20230143491A1 (en) 2023-05-11
US20210403439A1 (en) 2021-12-30
KR102865323B1 (ko) 2025-09-26
US11401246B2 (en) 2022-08-02
WO2020010309A1 (en) 2020-01-09
JP2021530560A (ja) 2021-11-11
MX2021000051A (es) 2021-03-25
CN112399873A (zh) 2021-02-23
AU2019297523A1 (en) 2021-02-25
IL279952B1 (en) 2024-07-01
CA3104529A1 (en) 2020-01-09
IL279952B2 (en) 2024-11-01
CO2021001277A2 (es) 2021-04-30
SA521420951B1 (ar) 2024-03-24

Similar Documents

Publication Publication Date Title
CN112399873B (zh) 三唑乙醇酸氧化酶抑制剂
US11098045B2 (en) Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof
TWI849782B (zh) 經雜芳基取代之吡啶及使用方法
CN103382201B (zh) 作为cftr调节剂的杂芳基衍生物
CN110022875A (zh) 治疗性抑制化合物
WO2007037534A1 (ja) ２－へテロアリール置換インドール誘導体
JP5301456B2 (ja) ヘテロアリールオキシキナゾリン誘導体
CN111727186B (zh) 双杂环取代的吡啶-2(1h)-酮衍生物、其制法与医药上的用途
US11147801B2 (en) Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
US12290507B2 (en) Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
WO2022089389A1 (zh) 杂环化合物及其制备方法、药物组合物和应用
CN114945559A (zh) 三唑乙醇酸氧化酶抑制剂的制备方法
CN103261193A (zh) 抑制白三烯生成的*二唑抑制剂
CN118184658A (zh) Usp1抑制剂
CN112341390B (zh) 用于制备靶向组蛋白甲基转移酶ezh2共价抑制剂的化合物及其制备方法和用途
CN114980886A (zh) 用于治疗草酸盐相关疾病的化合物和方法
WO2025021048A1 (zh) 一类多环化合物及其用途
CA3104529C (en) Triazole glycolate oxidase inhibitors
WO2024104317A1 (zh) 抑制15-pgdh的化合物及其用途
EP4673138A1 (en) Nbd1 modulators and methods of using the same
CN116239597A (zh) 一种嘧啶并吡咯类衍生物及其药用组合物和应用
HK40006420A (zh) 治疗性抑制化合物
HK40000783B (zh) 化合物及其用於降低尿酸水平的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: California, USA

Applicant after: Cantero treatment Co.,Ltd.

Address before: California, USA

Applicant before: Aofan biotechnology Co.

GR01 Patent grant
GR01 Patent grant